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Blood transfusion is a lifesaving intervention, having a
central role in patients' management. However, it is not
free of risks. One of the major challenges is Transfusion
Transmitted Infections (TTIs) by viruses, bacteria and
protozoa which are determined by their presence in the
donated blood and their survival during blood storage.
Important among these infections are viral hepatitis B, C,
Human Immunodeficiency Virus (HIV), and syphilis.
WHO recommends an additional screening for malaria,
Human T Lymphocyte Virus (HTLV) and Chagas disease
for some countries as per epidemiology. Dengue,
hepatitis E, Parvovirus, Chikungunya and West Nile Viral
(WNV) infection constitute new emerging viruses.
Pathogens like Cretuzfeldt-Jacob variant disease
organism and Middle East Respiratory Syndrome
Coronavirus (MERS-CoV) are the dreaded ones though
there never has been an evidence of their transmission
through transfusion.1 Moreover, because of distinctive
storage temperature requirements (20 - 24ºC) for
platelets units, bacterial contamination remains a
potential threat for these blood products.
Strategies like donor interview, testing for disease
markers, appropriate storing, leuco-depletion have
significantly reduced the risk of TTIs. Besides, evidence-
based transfusion guidelines, directed towards judicious
usage of blood components, minimize the exposure of
patients to potentially infectious blood or blood products.
Recent technology like Nucleic Acid Testing (NAT)
reduces the risk of window period donations for Human
Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV),
and Hepatitis C Virus (HCV). Encouraging reports on
utilizing NAT have emerged from Southern2 and
Northern Pakistan.3 A recent meta-analysis showed that
weighted average for sero-prevalence is 2.3% for HBV
and 2.8% for HCV in our blood donors4 while risk of
window period donations is 1:13900, 1:10900 and
1:62600 respectively for Hepatitis C Virus (HCV),
Hepatitis B Virus (HBV) and Human Immunodeficiency
Virus (HIV).2
To eliminate window period donations and to guard
against new and ever-increasing infectious agents, tools
for pathogen inactivation have been established. One of
the most initial strategies in 1977 was heating of albumin
for preventing the transmission of hepatitis. Germany
was the pioneer for using heating to inactivate
pathogens in coagulation factor concentrates though at
the cost of reducing efficacy of clotting factors.
Recognition of Acquired Immuno Deficiency Syndrome
(AIDS) in 1985 in a hemophilia patient, provoked
the initiation of some virus inactivation procedures in
factor-VIII and factor-IX concentrates.
To address the issue, Solvent Detergent (SD) and
Methylene Blue (MB) / visible light were the initial
Pathogen Reduction Technologies (PRT). These were
used for removing viruses and parasites in plasma only,
as both were detrimental to cell membranes. SD,
followed by filtration method, inactivates lipid enveloped
viruses, protozoa and prions. However, SD treatment is
less effective in eliminating non-enveloped viruses like
hepatitis A and parvovirus B.5 Moreover, SD treated
plasma may lower clotting factors (factor V, VIII, vWF)
and ADAMTS-13 and protein S.6 MB gets incorporated
in the viral nucleic acid and produces free oxygen
radicals on exposure to visible light inhibiting viral
replication. MB is effective in eliminating enveloped
viruses as well as some non-enveloped viruses, but
cannot permeate bacterial and white cell walls.7
Therefore, it is ineffective in reducing bacteria or
preventing transfusion associated graft-versus-host
disease. Since MB remains localize to external surfaces,
it can be used as a pathogen reducing agent for plasma
only and not for cellular products.5 Latest technologies
use photosensitizers like amotosolen and riboflavin with
Ultraviolet (UV) rays to treat cellular products, e.g.
platelet concentrates.5 Both the agents intercalate with
nucleic acids of pathogens and upon UV light exposure
interfere with replication by either cross-linking
(amotosolen) or oxygen independent electron transfer
(riboflavin). Non-enveloped viruses such as hepatitis A
or E are resistant to inactivation by amotosolen.7
Moreover, amotosolen treated plasma should not be
used for neonates receiving phototherapy for
hyperbilirubinemia as it can produce erythema.7 These
are effective in removing enveloped viruses, bacteria,
protozoa and white cells from plasma and platelet units.
Amotosolen can prevent graft versus host disease
and transfusion transmitted cytomegaloviral infection.
Another rapidly evolving technology is using ultraviolet
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(UV) C without photosensitizers to interrupt synthesis of
nucleic acids by pathogens. It is a simple method using
UVC (245 nm) which effectively removes virus, bacteria
and parasite and does not require filtration of
photosensitive products. However, because of its short
wave length, it cannot penetrate turbid or protein
containing solutions. Therefore, UVC can be used to
reduce pathogens in apheresis or buffy coat platelets
containing additive solution.7 Though PRT is routinely
used in many European countries to treat plasma and
platelets, but currently it is not available for red cells
concentrates. However, clinical trials have reached such
a level where the technology will be utilized for red cells
as well.5
So where do we currently stand in terms of safety and
efficacy of PRT? Previous strategies for maximizing
safety of blood resulted in donor deferral and reduced
blood supply. Pathogen reduction is an attractive option
to remove/inactivate residual known and unknown
bacteria, viruses and protozoa. PRT was successfully
used for removing bacteria, Hepatitis A Virus (HAV),
parvovirus, Chikunguniya from blood products.
Moreover, PRT interrupts cell membranes of leucocytes
in donated blood with subsequent additional benefits of
preventing Cytomegalovirus (CMV) infection, febrile
reactions, platelet refractoriness and transfusion
associated host disease which has a high mortality rate.5
One of the major apprehensions for implementing PRT
was the toxicity of chemicals used. Extensive pre-clinical
toxicology for MB, amotosolen and riboflavin showed
that the toxicity risk for carcinogenesis, mutagenesis and
reproductive health is minimal as small quantities of
chemicals used.8 Moreover, UVC based technology is
devoid of photoactive substances and, therefore, does
not induce harmful effects related to photoactive
substances.9 Similarly, solvent and detergent levels are
too small in SD plasma to impose health hazards. What
is the clinical utility of pathogen reduced blood products?
Six randomized clinical trials (RCTs, five based on
amotosolen and one on riboflavin), have been conducted
to determine the platelet increment in pathogen reduced
platelet transfusions in oncology patients.5 These trials
showed lower platelet increment and increased
frequency of platelet transfusions, with treated
compared to non-treated platelets. Similarly, two RCTs
studied pathogen reduced plasma (using amotosolen
and MB/SD) in hepatic coagulopathy.5 They concluded
that efficiency of treated vs. untreated plasma was
same; however, patients receiving MB treated
plasma required 14% more plasma infusion. More RCTs
are needed to evaluate the differences in clinical
outcomes in terms of bleeding and adverse effects of
pathogen reduced blood products. As per current
recommendations, PRT is used as an addition rather
than replacement for preventive strategies. Hence, PRT
will add to the existing cost of blood products. Most
comprehensive cost benefit analysis was done by
Custer et al. in Canada.10 They reported a cost of
$44.0/donation for their current screening for HIV, HBV,
HCV, WNV, HTLV1/2 and syphilis. Addition of PRT
added another $100/donation in its cost. Cost-benefit
ratio of whole blood PRT compared to current screens
and interventions was $1,276,000/quality-adjusted life-
year (QALY; 95% confidence interval [CI] approximation
600,000-3,313,000). However, as residual risk of TTIs is
already low in Canada, this estimated cost may be lower
for developing countries where risk of TTIs is high.
Hence, if PRT is adopted in Pakistan, it will be more cost
effective than reported in developed countries.
Moreover, interventions like discontinuation of viral or
syphilis testing with screening for malaria only, during its
seasonal peaks, may further increase the cost
effectiveness for pathogen reduced blood products in
countries like ours. Several of these technologies are
commercially available and are user-friendly, hence can
easily be acquired in Pakistan setting.
In conclusion, introduction of PRT is a paradigm shift in
the prevention of TTIs. It is anticipated that PRT will
revolutionize the blood safety programs and may
replace conventional screening technology.
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